292 related articles for article (PubMed ID: 22054506)
1. New algorithm for OHSS prevention.
Papanikolaou EG; Humaidan P; Polyzos N; Kalantaridou S; Kol S; Benadiva C; Tournaye H; Tarlatzis B
Reprod Biol Endocrinol; 2011 Nov; 9():147. PubMed ID: 22054506
[TBL] [Abstract][Full Text] [Related]
2. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
Orvieto R
J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
[TBL] [Abstract][Full Text] [Related]
3. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
[TBL] [Abstract][Full Text] [Related]
4. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
[TBL] [Abstract][Full Text] [Related]
5. Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study.
Abdulkhalikova D; Bokal EV; Stimpfel M; Ciglar P; Korosec S
Front Endocrinol (Lausanne); 2022; 13():826411. PubMed ID: 35464066
[TBL] [Abstract][Full Text] [Related]
6. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
7. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
8. Ovarian stimulation for freeze-all IVF cycles: a systematic review.
Mizrachi Y; Horowitz E; Farhi J; Raziel A; Weissman A
Hum Reprod Update; 2020 Jan; 26(1):118-135. PubMed ID: 31867625
[TBL] [Abstract][Full Text] [Related]
9. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-Releasing Hormone-Agonist Triggering and a Freeze-All Approach: The Final Step in Eliminating Ovarian Hyperstimulation Syndrome?
Davenport MJ; Vollenhoven B; Talmor AJ
Obstet Gynecol Surv; 2017 May; 72(5):296-308. PubMed ID: 28558117
[TBL] [Abstract][Full Text] [Related]
12. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
Griesinger G
Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
[TBL] [Abstract][Full Text] [Related]
13. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
Atkinson P; Koch J; Ledger WL
Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
[TBL] [Abstract][Full Text] [Related]
14. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.
Griesinger G; Diedrich K; Devroey P; Kolibianakis EM
Hum Reprod Update; 2006; 12(2):159-68. PubMed ID: 16254001
[TBL] [Abstract][Full Text] [Related]
15. Equivalent live-birth rate in antagonist IVF/ICSI protocol after oocyte triggering with GnRH agonist supplemented with 1500 r-hCG the day of oocyte retrieval vs r-hCG : A case-control study.
Cherrière F; Arvis P; Le Pabic E; Bidet M; Jaffré F; Guivarc'h-Levêque A
J Gynecol Obstet Hum Reprod; 2020 Jun; 49(6):101702. PubMed ID: 32018042
[TBL] [Abstract][Full Text] [Related]
16. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
17. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
18. Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study.
Lin YH; Huang MZ; Hwang JL; Chen HJ; Hsieh BC; Huang LW; Tzeng CR; Seow KM
J Assist Reprod Genet; 2013 Jun; 30(6):753-9. PubMed ID: 23606010
[TBL] [Abstract][Full Text] [Related]
19. A Second Dose of GnRHa in Combination with Luteal GnRH Antagonist May Eliminate Ovarian Hyperstimulation Syndrome in Women with ≥30 Follicles Measuring ≥11 mm in Diameter on Trigger Day and/or Pre-trigger Peak Estradiol Exceeding 10 000 pg/mL.
Deng L; Li XL; Ye DS; Blockeel C; Zhou XY; Chen SL; Chen X
Curr Med Sci; 2019 Apr; 39(2):278-284. PubMed ID: 31016522
[TBL] [Abstract][Full Text] [Related]
20. Luteal phase support with GnRH agonist does not eliminate the risk for ovarian hyperstimulation syndrome.
Friedler S; Grin L
Gynecol Endocrinol; 2019 May; 35(5):368-369. PubMed ID: 30614333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
